SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the December 2023 quarter moved up 42.75% to Rs. 129.77 millions as compared to Rs. 90.91 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -49.77 millions as compared to Net Loss of Rs. -55.55 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 improved to -20.60% as compared to -29.64% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 129.77 90.91 42.75 384.48 406.74 -5.47 521.34 597.03 -12.68
Other Income 0.29 0.23 26.09 2.41 4.27 -43.56 6.20 11.56 -46.37
PBIDT -20.60 -29.64 -30.50 -53.69 -107.30 -49.96 -151.59 -328.39 -53.84
Interest 11.86 8.98 32.07 34.17 19.44 75.77 29.73 53.91 -44.85
PBDT -32.46 -38.62 -15.95 -87.86 -126.74 -30.68 -181.32 -382.30 -52.57
Depreciation 17.31 16.93 2.24 50.95 50.79 0.32 65.59 62.97 4.16
PBT -49.77 -55.55 -10.41 -138.81 -177.53 -21.81 -246.91 -445.27 -44.55
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -49.77 -55.55 -10.41 -138.81 -177.53 -21.81 -246.91 -445.27 -44.55
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -15.87 -32.60 -51.31 -13.96 -26.38 -47.07 -29.08 -55.00 -47.14

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×